BRPI0918103A2 - "método para o tratamento da dor em um indivíduo" - Google Patents

"método para o tratamento da dor em um indivíduo"

Info

Publication number: BRPI0918103A2
Authority: BR; Brazil
Prior art keywords: individual; treating pain; pain; treating
Prior art date: 2008-12-22

Application number

BRPI0918103A

Other languages

English (en)

Inventor

Andrew David Cook

John Allan Hamilton

Original Assignee

Univ Melbourne

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-22

Filing date

2009-12-21

Publication date

2016-07-05

2009-12-21 Application filed by Univ Melbourne filed Critical Univ Melbourne

2016-07-05 Publication of BRPI0918103A2 publication Critical patent/BRPI0918103A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Rheumatology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

BRPI0918103A 2008-12-22 2009-12-21 "método para o tratamento da dor em um indivíduo" BRPI0918103A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US13968708P	2008-12-22	2008-12-22
US16449109P	2009-03-30	2009-03-30
PCT/AU2009/001671 WO2010071923A1 (en)	2008-12-22	2009-12-21	Pain treatment

Publications (1)

Publication Number	Publication Date
BRPI0918103A2 true BRPI0918103A2 (pt)	2016-07-05

Family

ID=42286785

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0918103A BRPI0918103A2 (pt)	2008-12-22	2009-12-21	"método para o tratamento da dor em um indivíduo"

Country Status (12)

Country	Link
US (3)	US8475796B2 (pt)
EP (2)	EP2387418B1 (pt)
JP (3)	JP5674677B2 (pt)
KR (1)	KR101761324B1 (pt)
CN (2)	CN102256621B (pt)
AU (2)	AU2009329811B2 (pt)
BR (1)	BRPI0918103A2 (pt)
CA (1)	CA2747206C (pt)
ES (2)	ES2685895T3 (pt)
HK (2)	HK1255046A1 (pt)
RU (2)	RU2712166C2 (pt)
WO (1)	WO2010071923A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102256621B (zh) *	2008-12-22	2017-12-12	墨尔本大学	疼痛治疗
SI2376121T1 (sl)	2008-12-22	2016-07-29	The University Of Melbourne	Zdravljenje osteoartritisa
UA117228C2 (uk)	2012-09-20	2018-07-10	Морфосис Аґ	Фармацевтична композиція, що містить антитіло до gm-csf
KR20210021153A (ko) *	2012-09-20	2021-02-24	모르포시스 아게	류마티스 관절염에 대한 치료
AR093297A1 (es)	2012-10-31	2015-05-27	Amgen Res (Munich) Gmbh	Formulacion liquida que comprende un compuesto neutralizante de gm-csf
EP2914289B1 (en) *	2012-10-31	2019-05-22	Takeda GmbH	Lyophilized formulation comprising gm-csf neutralizing compound
US20160024200A1 (en) *	2013-03-14	2016-01-28	John Schrader	Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof
KR20220045064A (ko)	2013-08-30	2022-04-12	다케다 야쿠힌 고교 가부시키가이샤	류마티스성 관절염의 치료에서 또는 진통제로서 사용하기 위한 gm-csf 중화 항체
DK3328887T3 (da)	2016-09-19	2021-09-20	I Mab Biopharma Hangzhou Co Ltd	Anti-GM-CSF antistoffer og anvendelser deraf
CN107840885B (zh) *	2016-09-19	2020-11-10	天境生物科技(上海)有限公司	Gm-csf抗体及其用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU630496B2 (en) *	1989-07-14	1992-10-29	Schering Corporation	Antagonists of gm-csf derived from the carboxyl terminus
DK0486572T3 (da)	1989-08-11	1998-05-04	Amrad Corp Ltd	Forbedringer i granulocyt-makrofag-kolonistimulerende faktorreceptor og derivater deraf
US5747032A (en)	1990-08-10	1998-05-05	Amrad Corporation Limited	Monoclonal antibody to human granulocyte macrophage colony stimulating factor
EP0673389A1 (en) *	1992-11-19	1995-09-27	Dana Farber Cancer Institute	Antibodies for gm-csf receptor and uses thereof
EP0859841B1 (en)	1995-08-18	2002-06-19	MorphoSys AG	Protein/(poly)peptide libraries
AUPP525198A0 (en)	1998-08-13	1998-09-03	Medvet Science Pty. Ltd.	Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof
US7108852B2 (en)	2000-03-20	2006-09-19	Warner-Lambert Company Llc	Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en)	2000-05-08	2008-11-25	The University Of Melbourne	Method of treatment and agents useful for same
SE0102067D0 (sv) *	2001-06-11	2001-06-11	A & Science Invest Ab	Prevention of neovascularization of intervertebral discs and/or of tissues with local inflammation
EP1442132A2 (en)	2001-10-26	2004-08-04	Novartis AG	Methods for the treatment of osteoarthritis and compositions thereof
ES2365606T3 (es)	2002-02-13	2011-10-07	Ludwig Institute For Cancer Research Ltd.	Anticuerpos contra gm-csf quiméricos.
AU2002950957A0 (en) *	2002-08-23	2002-09-12	The Walter And Eliza Hall Institute Of Medical Research	A method of treatment and prophylaxis
US7569364B2 (en)	2002-12-24	2009-08-04	Pfizer Inc.	Anti-NGF antibodies and methods using same
US20040241755A1 (en)	2003-06-02	2004-12-02	Pfizer Inc.	Human cell assay to determine effect of sample compounds on Col2 enhancer expression
CA2561530C (en)	2004-03-31	2014-04-22	Kazuwa Nakao	Therapeutic or prophylactic agent for arthritis
EP1593690B1 (en)	2004-05-05	2009-07-01	Micromet AG	Preparation of ScFv antibody fragments
DK1874819T3 (en)	2005-04-18	2015-08-31	Amgen Res Munich Gmbh	ANTIBODY FOR NEUTRALIZATION OF HUMAN GRANULOCYTE / MACROPHAG COLONY STIMULATING FACTOR
SI3620171T1 (sl) *	2005-05-18	2022-09-30	Morphosys Ag	Protitelesa proti GM-CSF in uporabe zanje
JP4736037B2 (ja)	2005-10-26	2011-07-27	株式会社イーベック	ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
AU2006321367B2 (en)	2005-12-01	2011-11-03	Domantis Limited	Competitive domain antibody formats that bind Interleukin 1 Receptor type 1
KR101486183B1 (ko)	2006-02-08	2015-01-28	모르포테크, 인크.	항원성 ｇｍ-ｃｓｆ 펩티드 및 ｇｍ-ｃｓｆ에 대한 항체
CN103641915B (zh)	2006-03-27	2017-04-12	医学免疫有限公司	Gm‑csf受体结合元件
US7741273B2 (en) *	2006-04-13	2010-06-22	Warsaw Orthopedic, Inc.	Drug depot implant designs
CA2670288C (en)	2006-11-21	2015-10-27	Kalobios Pharmaceuticals, Inc.	Methods of treating chronic inflammatory diseases using a gm-csf antagonist
US7879856B2 (en)	2006-12-22	2011-02-01	Rigel Pharmaceuticals, Inc.	Diaminothiazoles useful as Axl inhibitors
US20110044996A1 (en)	2007-05-23	2011-02-24	Charles Mackay	Neutralizing antibodies
TW200918553A (en)	2007-09-18	2009-05-01	Amgen Inc	Human GM-CSF antigen binding proteins
AU2008323608A1 (en)	2007-11-12	2009-05-22	Crc For Asthma And Airways Ltd	Epitope for neutralizing antibodies
AR069290A1 (es)	2007-11-13	2010-01-13	Evec Inc	Anticuerpos monoclonales que se unen al hgm -csf (factor estimulante de la colonia de granulocitos-macrofagos) y las composiciones medicas que los comprenden
NZ588850A (en)	2008-04-28	2012-12-21	Kalobios Pharmaceuticals Inc	Antibodies to granulocyte-macrophage colony-stimulating factor
CN102256621B (zh) *	2008-12-22	2017-12-12	墨尔本大学	疼痛治疗
SI2376121T1 (sl)	2008-12-22	2016-07-29	The University Of Melbourne	Zdravljenje osteoartritisa
CN102459340A (zh)	2009-04-23	2012-05-16	特罗科隆科学有限公司	粒性白血细胞-巨噬细胞菌落-刺激因子(gm-csf)中和抗体

2009
- 2009-12-21 CN CN200980151639.7A patent/CN102256621B/zh active Active
- 2009-12-21 WO PCT/AU2009/001671 patent/WO2010071923A1/en active Application Filing
- 2009-12-21 CA CA2747206A patent/CA2747206C/en active Active
- 2009-12-21 KR KR1020117017019A patent/KR101761324B1/ko active IP Right Grant
- 2009-12-21 EP EP09833923.7A patent/EP2387418B1/en active Active
- 2009-12-21 BR BRPI0918103A patent/BRPI0918103A2/pt not_active Application Discontinuation
- 2009-12-21 EP EP18170226.7A patent/EP3381471B1/en active Active
- 2009-12-21 US US13/140,839 patent/US8475796B2/en active Active
- 2009-12-21 CN CN201711112956.0A patent/CN108014335A/zh active Pending
- 2009-12-21 AU AU2009329811A patent/AU2009329811B2/en active Active
- 2009-12-21 RU RU2016102346A patent/RU2712166C2/ru active
- 2009-12-21 ES ES09833923.7T patent/ES2685895T3/es active Active
- 2009-12-21 JP JP2011541029A patent/JP5674677B2/ja active Active
- 2009-12-21 RU RU2011127333A patent/RU2630969C2/ru active
- 2009-12-21 ES ES18170226T patent/ES2978209T3/es active Active
2013
- 2013-05-28 US US13/903,009 patent/US9352034B2/en active Active
2014
- 2014-07-04 JP JP2014138170A patent/JP6147704B2/ja active Active
2016
- 2016-01-18 AU AU2016200267A patent/AU2016200267B2/en active Active
- 2016-04-29 US US15/142,746 patent/US9834599B2/en active Active
2017
- 2017-04-05 JP JP2017074868A patent/JP2017149740A/ja active Pending
2018
- 2018-11-07 HK HK18114170.3A patent/HK1255046A1/zh unknown
- 2018-11-09 HK HK18114356.9A patent/HK1255227A1/zh unknown

Also Published As

Publication number	Publication date
HK1255046A1 (zh)	2019-08-02
AU2009329811A1 (en)	2010-07-01
EP3381471A1 (en)	2018-10-03
ES2978209T3 (es)	2024-09-09
EP3381471C0 (en)	2024-03-20
US20110287027A1 (en)	2011-11-24
CA2747206A1 (en)	2010-07-01
EP2387418B1 (en)	2018-06-13
RU2712166C2 (ru)	2020-01-24
AU2016200267B2 (en)	2017-09-07
AU2016200267A1 (en)	2016-02-11
JP2014224123A (ja)	2014-12-04
JP6147704B2 (ja)	2017-06-14
AU2009329811B2 (en)	2016-02-25
RU2016102346A (ru)	2018-11-20
EP2387418A4 (en)	2013-07-17
US9352034B2 (en)	2016-05-31
RU2016102346A3 (pt)	2019-07-29
JP2012512814A (ja)	2012-06-07
EP2387418A1 (en)	2011-11-23
ES2685895T3 (es)	2018-10-15
JP2017149740A (ja)	2017-08-31
WO2010071923A1 (en)	2010-07-01
CA2747206C (en)	2018-04-24
CN102256621A (zh)	2011-11-23
RU2011127333A (ru)	2013-01-27
US20160311896A1 (en)	2016-10-27
RU2630969C2 (ru)	2017-09-15
KR101761324B1 (ko)	2017-07-25
EP3381471B1 (en)	2024-03-20
US9834599B2 (en)	2017-12-05
US20130243791A1 (en)	2013-09-19
US8475796B2 (en)	2013-07-02
CN102256621B (zh)	2017-12-12
KR20110117659A (ko)	2011-10-27
HK1255227A1 (zh)	2019-08-09
JP5674677B2 (ja)	2015-02-25
CN108014335A (zh)	2018-05-11

Publication	Publication Date	Title
BRPI0918103A2 (pt)	2016-07-05	"método para o tratamento da dor em um indivíduo"
BRPI0906099A2 (pt)	2015-07-21	"método de tratamento do câncer em um indivíduo"
BRPI0810806A2 (pt)	2014-10-29	Método para tratar uma lesão cutânea em um indivíduo
BRPI0916049A2 (pt)	2015-11-10	"dispositivo para tratamento da cavidade dental e método para tratamento da cavidade dental"
BRPI0914902A2 (pt)	2017-06-20	composição farmacêutica e método para tratamento de mal de parkinson
BRPI0814776A2 (pt)	2015-03-03	Método para manter consistência para tratamentos de distribuição de droga em aerossol, e, aparelho para distribuição de droga em aerossol
BRPI0811589A2 (pt)	2014-10-29	Composição farmacêutica e método para tratar câncer
BRPI0813725A2 (pt)	2014-12-30	Métodos e composições para tratamento de doenças
BRPI0818963A2 (pt)	2015-05-05	Conjugado anticorpo-molécula parceira e método para tratar câncer em um indivíduo
BRPI0819075A2 (pt)	2014-10-07	Método para tratar púrpura em um indivíduo e método para diminuir a púrpura em um indivíduo antes de um procedimento cirúrgico
BRPI0815283A2 (pt)	2015-07-14	Equipamento para o tratamento da biomassa, método para o tratamento da biomassa, biomassa tratada e hidrolisado
BRPI0916472A2 (pt)	2019-09-24	dispositivo de tratamento de ferimento, método para tratamento de um ferimento e dispositivo de tratamento de ferimento
BRPI0908503A2 (pt)	2015-09-29	partícula com um diâmetro menor que 2mm, e, composição para o tratamento de tecidos
BRPI0820212A2 (pt)	2015-06-16	Dispositivo para tratamento de fraturas, método para tratamento de fraturas, e, kit para tratamento de fraturas
BRPI0817664A2 (pt)	2015-03-24	Nanopartículas, método para preparar nanopartículas e método para tratar terapeuticamente ou profilaticamente um indivíduo
BRPI0919804A2 (pt)	2015-08-18	Métodos e composição para o tratemento de problemas dermatológicos e/ou condições de cabelo
BRPI0909627A2 (pt)	2018-04-10	métodos, composições e kits para tratar dores e pruridos
BRPI0906328A2 (pt)	2015-07-07	"método para reduzir sulfeto de hidrogênio em asfalto, método para tratar asfalto e composição sequestrante de sulfeto de hidrogênio"
BRPI0812585A2 (pt)	2015-02-18	Aparelho de tratamento de redução e método de tratamento de redução
BRPI0919238A2 (pt)	2019-09-24	métodos e composições para o tratamento de câncer
BRPI0909164A2 (pt)	2016-06-21	método e composições para o tratamento de câncer
IL273964B (en)	2021-12-01	A cosmetic method for the treatment of skin tissue
BRPI0923534A2 (pt)	2016-04-26	composição e método para tratamento de doenças de pele
BRPI1006145A2 (pt)	2017-05-30	"composição e método para tratamento de diabetes".
BRPI0905996A2 (pt)	2015-06-30	"método e aparelho para secagem contínua"

Legal Events

Date	Code	Title	Description
2018-03-06	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-07-16	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-09-17	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2020-06-23	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2021-06-01	B350	Update of information on the portal [chapter 15.35 patent gazette]
2022-12-06	B09B	Patent application refused [chapter 9.2 patent gazette]
2023-10-03	B09B	Patent application refused [chapter 9.2 patent gazette]	Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.